The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Dyskinesias and motor fluctuations in Parkinson's disease
Abstract
We investigated the prevalence of dyskinesias and motor fluctuations, and the factors determining their occurrence, in a community-based population of patients with Parkinson's disease. Among 124 patients with Parkinson's disease, 87 (70%) had received a levodopa preparation. Among these 87 patients, 28% were experiencing treatment-induced dyskinesias and 40% response fluctuations. The prevalence of motor fluctuations was best predicted by disease duration and dose of levodopa, whereas dyskinesias could be best predicted by duration of treatment. Patients with a shorter time from symptom onset to initiation of levodopa and younger patients had developed motor complications earlier, and patients who had started treatment with a dopamine agonist had developed these treatment complications later. Although a satisfactory response to medication was associated with higher rates of motor complications, poor or moderate response was associated with lower quality of life in patients with a disease duration of </=5 years or >/=10 years. We conclude that motor fluctuations are most strongly related to disease duration and dose of levodopa, and dyskinesias to duration of levodopa treatment. However, poorer quality of life associated with inadequate dosage of levodopa may be the price for a low rate of motor complications in patients with Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Peto, V., Jenkinson, C., Fitzpatrick, R., & Greenhall, R. (1995) · Quality of Life Research · doi:10.1007/bf02260863 · Cited by 1,204
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
Schrag, A., Ben-Shlomo, Y., & Quinn, N. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04137-9 · Cited by 642
Self-citationBallard, P. A., Tetrud, J. W., & Langston, J. W. (1985) · Neurology · doi:10.1212/wnl.35.7.949 · Cited by 629
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE
Marsden, C. D., & Parkes, J. D. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91146-1 · Cited by 587
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Cited by
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
Rodriguez-Oroz, M. C., Obeso, J. A., Lang, A. E., Houeto, J.-L., Pollak, P., Rehncrona, S., Kulisevsky, J., Albanese, A., Volkmann, J., Hariz, M. I., et al. (2005) · Brain · doi:10.1093/brain/awh571 · Cited by 1,057
Self-citationThe scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
A review of Parkinson's disease
Davie, C. A. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn013 · Cited by 855
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Parkinson's disease symptoms: The patient's perspective
Politis, M., Wu, K., Molloy, S., G. Bain, P., Chaudhuri, K. R., & Piccini, P. (2010) · Movement Disorders · doi:10.1002/mds.23135 · Cited by 647
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 547
Impact of the motor complications of Parkinson's disease on the quality of life
Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., & Durif, F. (2005) · Movement Disorders · doi:10.1002/mds.20279 · Cited by 521
Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G. (2007) · Movement Disorders · doi:10.1002/mds.21475 · Cited by 464
A clinico-pathological study of subtypes in Parkinson's disease
Selikhova, M., Williams, D. R., Kempster, P. A., Holton, J. L., Revesz, T., & Lees, A. J. (2009) · Brain · doi:10.1093/brain/awp234 · Cited by 461
An update on the diagnosis and treatment of Parkinson disease
Rizek, P., Kumar, N., & Jog, M. S. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151179 · Cited by 447
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up
Schupbach, W. M. M. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.063206 · Cited by 425
Levodopa Is a Double‐Edged Sword for Balance and Gait in People With Parkinson's Disease
Curtze, C., Nutt, J. G., Carlson‐Kuhta, P., Mancini, M., & Horak, F. B. (2015) · Movement Disorders · doi:10.1002/mds.26269 · Cited by 404
Poewe, W. H., Rascol, O., Quinn, N., Tolosa, E., Oertel, W. H., Martignoni, E., Rupp, M., & Boroojerdi, B. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70108-4 · Cited by 398
Self-citationSlow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease
Alonso-Frech, F. (2006) · Brain · doi:10.1093/brain/awl103 · Cited by 358
The role of small intestinal bacterial overgrowth in Parkinson's disease
Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25522 · Cited by 344
Current approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Cilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Levodopa for the Treatment of Parkinson's Disease
LeWitt, P. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0800326 · Cited by 312
Cardoso, F., Seppi, K., Mair, K. J., Wenning, G. K., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70494-x · Cited by 294
Clinical characteristics in early Parkinson's disease in a central California population‐based study
Kang, G. A., Bronstein, J. M., Masterman, D. L., Redelings, M., Crum, J. A., & Ritz, B. (2005) · Movement Disorders · doi:10.1002/mds.20513 · Cited by 266
Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia
Cenci, M. A. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.005 · Cited by 265
Hauser, R. A., Rascol, O., Korczyn, A. D., Jon Stoessl, A., Watts, R. L., Poewe, W., De Deyn, P. P., & Lang, A. E. (2007) · Movement Disorders · doi:10.1002/mds.21743 · Cited by 252
Levodopa in the treatment of Parkinson's disease
Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02697.x · Cited by 231
Moore, S. T., Yungher, D. A., Morris, T. R., Dilda, V., MacDougall, H. G., Shine, J. M., Naismith, S. L., & Lewis, S. J. (2013) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/1743-0003-10-19 · Cited by 204
“However, FOG commonly shows only partial response to levodopa [22], and the benefits of increasing levodopa dosage in reducing FOG must be balanced with the increased likelihood of levodopa-induced dyskinesias, also associated with a greater fall risk [25].”
BackgroundThe Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.042 · Cited by 203
“Many of the non-motor symptoms are unresponsive to dopaminergic treatments (Lee and Koh, 2015; Schrag and Quinn, 2000).”
BackgroundMahadevan, N., Demanuele, C., Zhang, H., Volfson, D., Ho, B., Erb, M. K., & Patel, S. (2020) · npj Digital Medicine · doi:10.1038/s41746-019-0217-7 · Cited by 138
“However, as the disease progresses, patients often develop complications like dyskinesias and motor fluctuations, which reduces the efficacy of levodopa-based treatments.(6) Despite many advances in the development of therapies for managing PD symptoms, there are currently no available therapies that slow disease prog…”
BackgroundMotor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features
Ray Chaudhuri, K., Poewe, W., & Brooks, D. (2018) · Movement Disorders · doi:10.1002/mds.27386 · Cited by 121
“Some observational studies in routine care settings have shown somewhat lower figures of around 30% after 5 years of treatment.(14) There is considerable variability depending on age and other risk factors in the populations studied with particularly high rates in young-onset cases (see below).”
BackgroundPerez-Pardo, P., de Jong, E. M., Broersen, L. M., van Wijk, N., Attali, A., Garssen, J., & Kraneveld, A. D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00057 · Cited by 74
Association of Parkinson’s Disease With Microbes and Microbiological Therapy
Chen, Z.-J., Liang, C.-Y., Yang, L.-Q., Ren, S.-M., Xia, Y.-M., Cui, L., Li, X.-F., & Gao, B.-L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.619354 · Cited by 45
Boroojerdi, B., Ghaffari, R., Mahadevan, N., Markowitz, M., Melton, K., Morey, B., Otoul, C., Patel, S., Phillips, J., Sen-Gupta, E., et al. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.11.024 · Cited by 43
van Laar, T. (2003) · CNS Drugs · doi:10.2165/00023210-200317070-00002 · Cited by 43
Metadata
- Authors
- Schrag, A., & Quinn, N.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-11
- Volume
- 123
- Issue
- 11
- Pages
- 2297-2305
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2034825135
- Cited by
- 600
- References
- 34
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.